Skip to main content
Erschienen in: Indian Journal of Gastroenterology 1/2020

24.04.2020 | Original Article

The effect of PNPLA3 polymorphism as gain in function mutation in the pathogenesis of non-alcoholic fatty liver disease

verfasst von: Anıl Delik, Hikmet Akkız, Sadık Dinçer

Erschienen in: Indian Journal of Gastroenterology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Non-alcoholic fatty liver disease (NAFLD) is often associated with metabolic syndrome (type 2 diabetes, hypertension, hypertriglyceridemia, insulin resistance, and obesity). NAFLD is multi-factorial in pathogenesis with some genetic predisposition. The variant patatin-like phospholipase domain–containing protein 3 (PNPLA3) is known to be an independent risk factor for hepatocellular cancer (HCC). The aim of this study was to investigate the role of PNPLA3 polymorphism as the risk factor for NAFLD.

Methodology

Patients had histological, ultrasonographic, biopsy evidence of NAFLD (n=248) and 81 controls were studied for PNPLA3 polymorphism. PNPLA3 genotyping was done from peripheral blood DNA by real-time polymerase chain reaction (RT-PCR).

Results

PNPLA3 genotyping of the groups NAFLD (CC [n = 76], CG [n = 83], GG [n = 89]) and control (CC [n= 42], CG [n = 22], GG [n = 17]) was determined. In the patient group, the G allele was 261 (52.63%) and the C allele was 235 (47.37%), whereas in the control group, the G allele was 56 (34.54%) and the C allele was 106 (65.43%). In our study, 53 out of 174 women had GG allele and 54 out of 155 men had GG allele.

Conclusion

The findings suggest that there is a predominant relationship between men with PNPLA3 I148M variant with NAFLD in women. Patients with NAFLD carrying PNPLA3 rs738409 G>C variant are at higher risk of NAFLD.
Literatur
1.
Zurück zum Zitat Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
2.
Zurück zum Zitat Gallego-Duran R, Romero-Gomez M. Epigenetic mechanisms in nonalcoholic fatty liver disease: an emerging field. World J Hepatol. 2015;7:2497–502.CrossRef Gallego-Duran R, Romero-Gomez M. Epigenetic mechanisms in nonalcoholic fatty liver disease: an emerging field. World J Hepatol. 2015;7:2497–502.CrossRef
3.
Zurück zum Zitat Carulli L, Canedi I, Rondinella S, et al. Genetic polymorphisms in non- alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. Dig Liver Dis. 2009;41:823–8.CrossRef Carulli L, Canedi I, Rondinella S, et al. Genetic polymorphisms in non- alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. Dig Liver Dis. 2009;41:823–8.CrossRef
4.
Zurück zum Zitat Willner IR, Waters B, Patil SR. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol. 2001;96:2957–61.CrossRef Willner IR, Waters B, Patil SR. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol. 2001;96:2957–61.CrossRef
5.
Zurück zum Zitat Mohanty SR, Troy TN, Huo D. Influence of ethnicity on histological differences in nonalcoholic fatty liver disease. J Hepatol. 2009;50:797–804.CrossRef Mohanty SR, Troy TN, Huo D. Influence of ethnicity on histological differences in nonalcoholic fatty liver disease. J Hepatol. 2009;50:797–804.CrossRef
6.
Zurück zum Zitat Zain SM, Mohamed R, Mahadeva S, et al. A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease. Hum Genet. 2012;131:1145–52.CrossRef Zain SM, Mohamed R, Mahadeva S, et al. A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease. Hum Genet. 2012;131:1145–52.CrossRef
7.
Zurück zum Zitat Naik A, Košir R, Rozman D. Genomic aspects of NAFLD pathogenesis. Genomics. 2013;102:84–95.CrossRef Naik A, Košir R, Rozman D. Genomic aspects of NAFLD pathogenesis. Genomics. 2013;102:84–95.CrossRef
8.
Zurück zum Zitat Puppala J, Siddapuram SP, Akka J, Munshi A. Genetics of nonalcoholic fatty liver disease: an overview. J Genet Genomics. 2013;40:15–22.CrossRef Puppala J, Siddapuram SP, Akka J, Munshi A. Genetics of nonalcoholic fatty liver disease: an overview. J Genet Genomics. 2013;40:15–22.CrossRef
9.
Zurück zum Zitat Browning JD. Common genetic variants and nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2013;11:1191–3.CrossRef Browning JD. Common genetic variants and nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2013;11:1191–3.CrossRef
10.
Zurück zum Zitat Kotronen A, Johansson LE, Johansson LM, et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia. 2009;52:1056–60.CrossRef Kotronen A, Johansson LE, Johansson LM, et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia. 2009;52:1056–60.CrossRef
11.
Zurück zum Zitat Hernaez R, McLean J, Lazo M, et al. Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol. 2013;11:1183–90.CrossRef Hernaez R, McLean J, Lazo M, et al. Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol. 2013;11:1183–90.CrossRef
12.
Zurück zum Zitat Takaki A, Kawai D, Yamamoto K. Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). Int J Mol Sci. 2014;15:7352–79.CrossRef Takaki A, Kawai D, Yamamoto K. Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). Int J Mol Sci. 2014;15:7352–79.CrossRef
13.
Zurück zum Zitat Hori M, Oniki K, Nakagava T, et al. Association between combination of glutathione-S-transferase M1, T1 and P1 genotypes and non-alcoholic fatty liver disease. Liver Int. 2009;29:164–8.CrossRef Hori M, Oniki K, Nakagava T, et al. Association between combination of glutathione-S-transferase M1, T1 and P1 genotypes and non-alcoholic fatty liver disease. Liver Int. 2009;29:164–8.CrossRef
14.
Zurück zum Zitat Xin YN, Zhao Y, Lin ZH, Jiang X, Xuan SY, Huang J. Molecular dynamics simulation of PNPLA3 I148M polymorphism reveals reduced substrate access to the catalytic cavity. Proteins. 2013;81:406–14. Xin YN, Zhao Y, Lin ZH, Jiang X, Xuan SY, Huang J. Molecular dynamics simulation of PNPLA3 I148M polymorphism reveals reduced substrate access to the catalytic cavity. Proteins. 2013;81:406–14.
15.
Zurück zum Zitat Smagris E, Basu Ray S, Li J, et al. Pnpla3I148M knock in mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology. 2015;61:108–18. Smagris E, Basu Ray S, Li J, et al. Pnpla3I148M knock in mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology. 2015;61:108–18.
16.
Zurück zum Zitat Pirazzi C, Adiels M, Burza MA, et al. Patatin like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol. 2012;57:1276–82.CrossRef Pirazzi C, Adiels M, Burza MA, et al. Patatin like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol. 2012;57:1276–82.CrossRef
17.
Zurück zum Zitat Valenti L, Rametta R, Ruscica M, et al. The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterol. 2012;12:111.CrossRef Valenti L, Rametta R, Ruscica M, et al. The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterol. 2012;12:111.CrossRef
18.
Zurück zum Zitat Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ; NASH CRN. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology. 2010;52:894–903. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ; NASH CRN. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology. 2010;52:894–903.
19.
Zurück zum Zitat Trépo E, Nahon P, Bontempi G, et al. Association between the PNPLA3 (rs738409 C& gt; G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data. Hepatology. 2014;59:2170–7.CrossRef Trépo E, Nahon P, Bontempi G, et al. Association between the PNPLA3 (rs738409 C& gt; G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data. Hepatology. 2014;59:2170–7.CrossRef
20.
Zurück zum Zitat Wang VW, Adams LA, Ledinghen VD, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH – current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15:461–78. Wang VW, Adams LA, Ledinghen VD, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH – current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15:461–78.
21.
Zurück zum Zitat Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.CrossRef Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.CrossRef
22.
Zurück zum Zitat Portillo-Sanchez P, Bril F, Maximos M, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab. 2015;100:2231–8.CrossRef Portillo-Sanchez P, Bril F, Maximos M, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab. 2015;100:2231–8.CrossRef
23.
Zurück zum Zitat Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010;5:145–71.CrossRef Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010;5:145–71.CrossRef
24.
Zurück zum Zitat Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med. 2012;52:59–69.CrossRef Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med. 2012;52:59–69.CrossRef
25.
Zurück zum Zitat Yamada H, Ohashi K, Suzuki K, et al. Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease. Clin Chim Acta. 2015;446:267–71.CrossRef Yamada H, Ohashi K, Suzuki K, et al. Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease. Clin Chim Acta. 2015;446:267–71.CrossRef
26.
Zurück zum Zitat Pingitore P, Pirazzi C, Mancina RM, et al. Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochim Biophys Acta. 1841;2014:574–80. Pingitore P, Pirazzi C, Mancina RM, et al. Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochim Biophys Acta. 1841;2014:574–80.
27.
Zurück zum Zitat He S, McPhaul C, Li JZ, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem. 2010;285:6706–15.CrossRef He S, McPhaul C, Li JZ, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem. 2010;285:6706–15.CrossRef
28.
Zurück zum Zitat Rae-Whitcombe SM, Kennedy D, Voyles M, Thompson MP. Regulation of the promoter region of the human adiponutrin/PNPLA3 gene by glucose and insulin. Biochem Biophys Res Commun. 2010;402:767–72.CrossRef Rae-Whitcombe SM, Kennedy D, Voyles M, Thompson MP. Regulation of the promoter region of the human adiponutrin/PNPLA3 gene by glucose and insulin. Biochem Biophys Res Commun. 2010;402:767–72.CrossRef
29.
Zurück zum Zitat Liu YM, Moldes M, Bastard JP, et al. A new gene regulated by energy balance in human adipose tissue. J Clin Endocrinol Metab. 2004;89:2684–9.CrossRef Liu YM, Moldes M, Bastard JP, et al. A new gene regulated by energy balance in human adipose tissue. J Clin Endocrinol Metab. 2004;89:2684–9.CrossRef
30.
Zurück zum Zitat Wilson PA, Gardner SD, Lambie NM, Commans SA, Crowther DJ. Characterization of the human patatin-like phospholipase family. J Lipid Res. 2006;47:1940–9. Wilson PA, Gardner SD, Lambie NM, Commans SA, Crowther DJ. Characterization of the human patatin-like phospholipase family. J Lipid Res. 2006;47:1940–9.
31.
Zurück zum Zitat Kumari M, Schoiswohl G, Chitraju C, et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab. 2012;15:691–702.CrossRef Kumari M, Schoiswohl G, Chitraju C, et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab. 2012;15:691–702.CrossRef
32.
Zurück zum Zitat Lee SS, Byoun YS, Jeong SH, et al. Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea. Dig Dis Sci. 2014;59:2967–74.CrossRef Lee SS, Byoun YS, Jeong SH, et al. Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea. Dig Dis Sci. 2014;59:2967–74.CrossRef
33.
Zurück zum Zitat Wang CW, Lin HY, Shin SJ, et al. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. Liver Int. 2011;31:1326–31.CrossRef Wang CW, Lin HY, Shin SJ, et al. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. Liver Int. 2011;31:1326–31.CrossRef
34.
Zurück zum Zitat Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53:1883–94.CrossRef Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53:1883–94.CrossRef
35.
Zurück zum Zitat Speliotes EK, Butler JL, Palmer CD, et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology. 2010;52:904–12.CrossRef Speliotes EK, Butler JL, Palmer CD, et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology. 2010;52:904–12.CrossRef
36.
Zurück zum Zitat Zhang L, You W, Zhang H, et al. PNPLA3 polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes: a meta-analysis. J Gastroenterol Hepatol. 2015;30:821–9.CrossRef Zhang L, You W, Zhang H, et al. PNPLA3 polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes: a meta-analysis. J Gastroenterol Hepatol. 2015;30:821–9.CrossRef
37.
Zurück zum Zitat Dentin R, Pégorier JP, Benhamed F. Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J Biol Chem. 2004;279:20314–26.CrossRef Dentin R, Pégorier JP, Benhamed F. Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J Biol Chem. 2004;279:20314–26.CrossRef
38.
Zurück zum Zitat Adams LA, White SW, Marsh JA, et al. Association between liver-specific gene polymorphisms and their expression levels with non- alcoholic fatty liver disease. Hepatology. 2013;57:590–600.CrossRef Adams LA, White SW, Marsh JA, et al. Association between liver-specific gene polymorphisms and their expression levels with non- alcoholic fatty liver disease. Hepatology. 2013;57:590–600.CrossRef
39.
Zurück zum Zitat Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121:91–100. Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121:91–100.
40.
Zurück zum Zitat Delik A, Dinçer S, Akkız H. The role of genetic and epigenetic factors in non alcoholic fatty liver disease (NAFLD) pathogenesis. Meta Gene. 2020;100647. Delik A, Dinçer S, Akkız H. The role of genetic and epigenetic factors in non alcoholic fatty liver disease (NAFLD) pathogenesis. Meta Gene. 2020;100647.
Metadaten
Titel
The effect of PNPLA3 polymorphism as gain in function mutation in the pathogenesis of non-alcoholic fatty liver disease
verfasst von
Anıl Delik
Hikmet Akkız
Sadık Dinçer
Publikationsdatum
24.04.2020
Verlag
Springer India
Erschienen in
Indian Journal of Gastroenterology / Ausgabe 1/2020
Print ISSN: 0254-8860
Elektronische ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-020-01026-x

Weitere Artikel der Ausgabe 1/2020

Indian Journal of Gastroenterology 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.